Listed by the USPTO as LEE, CHIHYI NMN
Tech Center 1600 • Art Units: 1628
This examiner grants 33% of resolved cases
LEE, CHIHYI NMN has 87 resolved cases and a 33.3% allowance rate. The interview lift is 61.1%, and the median time to allowance is 1302 days. The profile is assigned to Tech Center 1600 and Art Unit 1628. The large positive interview lift stands out against the 33.3% allowance rate, indicating that examiner interviews may be particularly important to response planning in this record. The 1302-day median also signals a lengthy prosecution path.
The listed companies are Skyhawk Therapeutics Inc., The United States Government as represented by the Department of Veterans Affairs, and Risen (Suzhou) Pharma Tech Co. Ltd. The leading firms are Casimir Jones, S.C., FOLEY & LARDNER LLP, and FOLEY HOAG, LLP (General). Practitioners may find early interview preparation useful when developing claim amendments and explaining technical distinctions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Final Rejection | Hoffmann-La Roche Inc. |
| 18273942 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | Final Rejection | The Regents of the University of Michigan |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Final Rejection | MINDSET PHARMA INC. |
| 18003807 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | Non-Final OA | The Cleveland Clinic Foundation |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Non-Final OA | United States Government as represented by the Department of Veterans Affairs |
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 17800208 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 18251129 | CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 18679695 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | Non-Final OA | H. Lundbeck A/S |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | Final Rejection | Amicus Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy33.3% of resolved applications examined by Chihyi Nmn Lee were allowed (87 resolved cases), compared with 26.0% across Art Unit 1628 over the last five years.
This examiner's interview lift is +61.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Chihyi Nmn Lee took 1,302 days on average from filing to allowance.
Chihyi Nmn Lee examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
